CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Cancers Année : 2023

CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data

Rosalind M. Glasspool
  • Fonction : Auteur
Caroline Kelly
  • Fonction : Auteur
Liz-Anne Lewsley
  • Fonction : Auteur
Karen Carty
  • Fonction : Auteur
Gunnar B. Kristensen
  • Fonction : Auteur
Josee-Lyne Ethier
  • Fonction : Auteur
Tatsuo Kagimura
  • Fonction : Auteur
Nozomu Yanaihara
  • Fonction : Auteur
Sabrina Chiara Cecere
  • Fonction : Auteur
Benoit You
  • Fonction : Auteur
Ingrid A Boere
  • Fonction : Auteur
Eric Pujade-Lauraine
  • Fonction : Auteur
Isabelle Ray-Coquard
Xavier Paoletti
  • Fonction : Auteur

Résumé

(1) Background: Cancer antigen 125 (CA-125) is a protein produced by ovarian cancer cells that is used for patients' monitoring. However, the best ways to analyze its decline and prognostic role are poorly quantified. (2) Methods: We leveraged individual patient data from the Gynecologic Cancer Intergroup (GCIG) meta-analysis (N = 5573) to compare different approaches summarizing the early trajectory of CA-125 before the prediction time (called the landmark time) at 3 or 6 months after treatment initiation in order to predict overall survival. These summaries included observed and estimated measures obtained by a linear mixed model (LMM). Their performances were evaluated by 10-fold cross-validation with the Brier score and the area under the ROC (AUC). (3) Results: The estimated value and the last observed value at 3 months were the best measures used to predict overall survival, with an AUC of 0.75 CI 95% [0.70; 0.80] at 24 and 36 months and 0.74 [0.69; 0.80] and 0.75 [0.69; 0.80] at 48 months, respectively, considering that CA-125 over 6 months did not improve the AUC, with 0.74 [0.68; 0.78] at 24 months and 0.71 [0.65; 0.76] at 36 and 48 months. (4) Conclusions: A 3-month surveillance provided reliable individual information on overall survival until 48 months for patients receiving first-line chemotherapy.
Fichier principal
Vignette du fichier
BPH_Cancers_2023_Karamouza.pdf (19.05 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04072476 , version 1 (18-04-2023)

Licence

Identifiants

Citer

Eleni Karamouza, Rosalind M. Glasspool, Caroline Kelly, Liz-Anne Lewsley, Karen Carty, et al.. CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data. Cancers, 2023, 15 (6), ⟨10.3390/cancers15061823⟩. ⟨hal-04072476⟩
14 Consultations
7 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More